Search Clinical Trials in the European Union

3-6 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
161-180 of 331 trials

Major Depressive Disorder: Liposom Forte with Citalopram

We are studying whether Liposom Forte can enhance and speed up the response to citalopram in elderly patients with Major Depressive Disorder. The trial also looks at the safety of this treatment.

Major Depression3-6 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesPsychiatry

Head and Neck Cancer: Carboplatin, Paclitaxel, and Cetuximab Study

We are studying a combination of three medications for patients with recurrent or metastatic head and neck squamous cell carcinoma who did not respond to previous treatments. The goal is to see if this combination improves response rates and overall survival.

Head and Neck Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Advanced Solid Tumors: Repotrectinib Study

We are testing a new treatment called repotrectinib for patients with advanced solid tumors that have specific genetic changes. The study aims to evaluate its safety and effectiveness in improving tumor response.

Advanced Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Diabetic Foot Ulcers: Comparing Two Treatments

We are studying whether Hypochlorous Acid or Polyhexamethylene biguanide helps heal diabetic foot ulcers more effectively. This trial will also look at healing size, depth, and quality of life for participants.

Diabetic Foot Ulcer3-6 monthsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesPartially RemoteDiabetologyInfectious DiseasesInternal Medicine

Thyroid Eye Disease: Batoclimab Extension Study

We are studying the long-term effects of batoclimab in people with Thyroid Eye Disease who previously participated in earlier studies. The goal is to see if it continues to help reduce eye bulging and benefits those who didn't respond to earlier treatments.

Thyroid Eye Disease3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOphthalmology

Systemic Juvenile Idiopathic Arthritis: Sarilumab Study

We are testing the medication sarilumab in children and adolescents with systemic juvenile idiopathic arthritis to find the best dose and understand its effects and safety.

Systemic Juvenile Idiopathic Arthritis (sJIA)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Migraine Treatment in Kids: Rimegepant Study

We are studying the effectiveness of rimegepant for treating migraines in children and adolescents aged 6 to under 18. The goal is to see if it helps relieve pain and other symptoms better than a placebo.

Migraine3-6 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesPartially RemoteNeurologyPediatrics

Non-Transfusion-Dependent Thalassemia: Mitapivat Study

We are studying whether Mitapivat can improve anemia in people with non-transfusion-dependent alpha or beta thalassemia. This trial compares the medication to a placebo to evaluate its effects.

Non-Transfusion Dependent Thalassemia3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematology

HIV Control: Pomalidomide Study

We are studying whether pomalidomide can help control HIV in people on treatment who take a break from their medication. The trial also examines its effects on the immune system and HIV persistence.

HIV-1 Infection3-6 monthsSafety phase (I)Efficacy phase (II)11-15 visitsStandard MedicinesInfectious DiseasesInternal Medicine

Generalized Myasthenia Gravis: DNTH103 Treatment Study

We are testing a new treatment called DNTH103 for adults with generalized myasthenia gravis. The study aims to evaluate its safety, tolerability, and effectiveness in managing symptoms.

Myasthenia Gravis3-6 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Severe Alcohol-Associated Hepatitis: INT-787 Study

We are testing a new medication, INT-787, for individuals with severe alcohol-associated hepatitis. The goal is to see if it can help slow down the progression of this serious liver disease.

Alcoholic Hepatitis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteHepatologyInternal Medicine

B-Cell Non-Hodgkin Lymphoma: BI-1206 Treatment Study

We are studying a new monoclonal antibody combined with rituximab, with or without acalabrutinib, for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to assess safety and how well it may work in reducing cancer cells.

Indolent B-Cell Non-Hodgkin Lymphoma3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Targeted Therapies for Moderate to Severe Crohn’s Disease

We are studying new targeted treatments for adults with moderate to severe Crohn’s disease. The goal is to evaluate their safety and effectiveness in managing this condition.

Crohn's Disease3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Invasive Aspergillosis: Olorofim vs. AmBisome®

We are studying a new treatment called olorofim for patients with invasive aspergillosis to see if it works better and is safer than the standard treatment, AmBisome®. This trial will also look at how these treatments affect patients' quality of life.

Invasive Fungal Infection3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Psychosis in Alzheimer's: ITI-1284 Study

We are evaluating a new medication, ITI-1284, for treating psychosis in patients with Alzheimer's disease. The study aims to see if it is more effective than a placebo in improving symptoms.

Psychosis associated with Alzheimer’s Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Oxygen Management During Anesthesia: The LOWOX Trial

We are studying whether a tailored approach to oxygen levels during anesthesia improves recovery and oxygen levels after surgery compared to standard fixed oxygen use. This trial involves patients undergoing various surgical procedures.

Surgery under General Anesthesia3-6 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngology

Botulinum Toxin for Spastic Equinovarus in Stroke Patients

We are exploring how a treatment with botulinum toxin type A affects muscle and nerve properties in people who have had their first stroke. This study aims to gather insights that could improve future treatments for spastic equinovarus.

Spastic Equinovarus in Stroke Patients3-6 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOrthopedics and Traumatology

Asthma Treatment: Tezepelumab Study

We are investigating whether tezepelumab can improve airway structure and function in patients with asthma compared to a placebo. This study will also explore its effects on lung health and asthma flare-ups.

Severe Asthma3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementAllergologyPulmonology

Axial Spondyloarthritis: NSAIDs vs. Biosimilar TNF Blockers

We are comparing the effectiveness of high-dose NSAIDs and a biosimilar TNF blocker for patients with axial spondyloarthritis who haven't responded to NSAIDs. The study will also look at side effects and inflammation levels.

Axial Spondyloarthritis3-6 monthsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Telmisartan for Portal Hypertension in Liver Disease

We are studying whether telmisartan can lower liver pressure in patients with advanced chronic liver disease and portal hypertension. This trial will also assess its safety and impact on quality of life.

Compensated Advanced Chronic Liver DiseasePortal Hypertension3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteHepatologyInternal Medicine